肝复乐联合肝动脉化疗栓塞术治疗肝细胞癌有效性的meta分析

Abstract
Figure/Table
References (25)
Related Citation (15)

Download: PDF (1636 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To systematically evaluate the effect of Ganfule combined with transcatheter arterial chemoembolization (TACE) on hepatocellular carcinoma. Methods PubMed, Medline, EMBase, Cochrane Library, CBM, CNKI, WanFang and VIP databases were all searched by computer, and the retrieval time was set up until December 2019. Randomized controlled trial of Ganfule combined with TACE in the treatment of hepatocellular carcinoma were screened. Meta-analysis was performed using RevMan5.3 software. Results A total of 11 studies were included in the analysis. Meta analysis showed that the effective rate of the experimental group was higher than that of the control group (OR = 2.05, 95%CI: 1.41, 2.97, P = 0.0001). The alanine aminotransferase level in the experimental group was lower than that in the control group (MD = -53.86, 95%CI: -73.33, -34.38, P < 0.000 01). The level of gamma-glutamyltransferase in the experimental group was lower than that in the control group (MD = -142.46, 95%CI: -152.88, -132.04, P < 0.000 01). The alpha fetal protein level of experimental group was lower than the control group (MD = -46.18, 95%CI: -55.70, -36.67, P < 0.000 01). The half-year survival rate in the experimental group was higher than that in the control group (OR = 3.65, 95%CI: 1.57, 8.51, P = 0.003). The one-year survival rate in the experimental group was higher than that in the control group (OR = 2.09, 95%CI: 1.47, 2.96, P < 0.0001). The two-year survival rate in the experimental group was higher than that in the control group (OR = 2.12, 95%CI: 1.21, 3.72, P = 0.008). Conclusion Compared with TACE alone, Ganfule combined with TACE in the treatment of hepatocellular carcinoma has a better clinical effect, which is worthy of promotion and application.

Key words： Ganfule Transcatheter arterial chemoembolization Hepatocellular carcinoma Randomized controlled trial Meta-analysis

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	YAN Yuanzhi1 TANG Heng1 YOU Jing2

Cite this article:

YAN Yuanzhi1 TANG Heng1 YOU Jing2. Meta-analysis of efficacy of Ganfule combined with TACE in the treatment of hepatocellular carcinoma[J]. 中国医药导报, 2020, 17(32): 87-91.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2020/V17/I32/87

[1] Marrero JA，Kulik LM，Sirlin CB，et al. Diagnosis，staging and management of hepatocellular carcinoma：2018 practice guidance by the American Association for the Study of Liver Diseases [J]. Hepatology，2018，68（2）：723-750.
[2] Bray F，Ferlay J，Soerjomataram I，et al. Global cancer statistics 2018：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin，2018，68（6）：394-424.
[3] 原发性肝癌诊疗规范（2019年版）[J].肝癌电子杂志，2020， 7（1）：5-23.
[4] 郅新，高健，郑晟旻，等.肝细胞癌经动脉化疗栓塞治疗的应用现状与研究进展[J].中华普通外科杂志，2019，34（8）：742-744.
[5] 程玉佩，张明香.中医药治疗原发性肝癌研究进展[J].辽宁中医药大学学报，2018，20（1）：167-169.
[6] 郭若闻，杨森，曹林，等.原发性肝癌的中西医结合治疗进展[J].中西医结合肝病杂志，2019，29（6）：573-576.
[7] 姚远，陈建建，周学良，等.TACE联合中药治疗不可切除肝细胞癌的研究进展[J].中华介入放射学电子杂志，2019，7（2）：130-134.
[8] 陈世平，黄瑞文.肝复乐配合介人治疗中晚期原发性肝癌85例疗效观察[J].疑难病杂志，2004，3（4）：225-226.
[9] 樊素梅.肝复乐胶囊联合肝动脉栓塞化疗治疗晚期肝癌的临床研究[J].临床医药文献杂志，2014，1（5）：53-54.
[10] 郝明志，陈武进，林海澜，等.肝动脉栓塞化疗联合肝复乐胶囊治疗晚期肝癌临床疗效观察[J].中南药学，2013， 11（2）：147-150.
[11] 刘冬梅.肝复乐胶囊联合肝动脉栓塞化疗治疗晚期肝癌的疗效观察[J].临床医药文献杂志，2016，3（2）：235-236.
[12] 刘霆.肝动脉栓塞化疗联合肝复乐胶囊治疗晚期肝癌临床疗效观察[J].黑龙江医学，2019，43（4）：364-365.
[13] 吴迪.肝复乐胶囊联合肝动脉栓塞化疗治疗晚期肝癌疗效及不良反应分析[J].中外医疗，2016，35（25）：98-100.
[14] 杨秋敏.TACE配合肝复乐治疗晚期原发性肝癌[J].光明中医，2003，18（108）：54-55.
[15] 尹剑，郭安红.肝动脉化疗栓塞联合肝复乐胶囊治疗原发性肝癌疗效及对血浆VEGF和内毒素的影响[J].现代中西医结合杂志，2018，27（24）：2696-2699.
[16] 张传光，杨明竹.肝动脉栓塞化疗联合口服肝复乐治疗中晚期原发性肝癌临床观察[J].中国现代实用医学杂志，2006，5（l0）：25-26.
[17] 张文华，梁春辉，贾文玲，等.125I粒子植入联合肝动脉栓塞化疗及肝复乐片治疗原发性肝癌的临床观察[J].中国医药指南，2015，13（25）：12-13.
[18] 周德江，何胜，翁敏.口服肝复乐联合经皮肝动脉栓塞化疗治疗中晚期原发性肝癌42例临床观察[J].医药前沿，2011，12（24）：10-11.
[19] 金学洙.中医药对肝癌治疗的研究进展[J].中国卫生标准管理，2016，7（23）：122-123.
[20] 魏明禄.中药复方制剂肝复乐胶囊联合替诺福韦治疗乙型肝炎肝硬化代偿期临床分析[J].中外医学研究，2017， 15（36）：38-40.
[21] 张继万，周建丽，张晓芳，等.Peg-IFN-α2a联合肝复乐胶囊对HbeAg阳性慢性乙型肝炎抗肝纤维化的疗效[J].武警医学，2017，28（3）：257-260.
[22] 王芳梅，刘金涛.恩替卡韦联合肝复乐胶囊治疗慢性乙型肝炎肝纤维化80例疗效观察[J].中国肝脏病杂志，2016，8（2）：95-98.
[23] 王博偲.肝恶性肿瘤原发癌与转移癌中医证候探析[D].沈阳：辽宁中医药大学，2017.
[24] 李存娣，曹伟娅，王健.血管内皮生长因子受体与肝细胞癌侵袭转移的关系[J].临床肝胆病杂志，2019，35（7）：1616-1620.
[25] 曹付春，韩雅莉，陈冰，等.地鳖纤溶蛋白对人脐静脉内皮细胞、肺癌、乳腺癌细胞VEGF和bFGF表达的影响[J].时珍国医国药，2011，22（8）：1827-1829.